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ABSTRACT 
 
Background: Enzalutamide, an oral androgen receptor inhibitor, significantly 
improved overall survival (OS) and radiographic progression-free survival 
(rPFS) versus placebo in the PREVAIL trial of men with chemotherapy-naïve 
metastatic castration-resistant prostate cancer (mCRPC). 
 
Objective: Assess effect of enzalutamide versus placebo in patients from 
PREVAIL based on site and extent of baseline disease. 
 
Design, Setting, and Participants: 1717 asymptomatic or minimally symptomatic 
patients were randomized to enzalutamide (n = 872) or placebo (n = 845). 
Subgroup analyses included: nonvisceral (only bone and/or nodal; n = 1513), 
visceral (lung and/or liver; n = 204), low-volume bone disease (<4 bone 
metastases; n = 867), high-volume bone disease (≥4 bone metastases; n = 850), 
lymph node only disease (n = 195). 
 
Intervention: Oral enzalutamide (160 mg) or placebo once daily while 
continuing androgen deprivation therapy. 
 
Outcome Measurements and Statistical Analysis: Coprimary endpoints 
(rPFS, OS) were prospectively evaluated in nonvisceral and visceral subgroups. 
All other efficacy analyses were post hoc. 
 
Results and Limitations: Enzalutamide improved rPFS versus placebo in patients 
with nonvisceral disease (hazard ratio [HR], 0.175; 95% confidence interval [CI], 0.14–
0.22), visceral disease (HR, 0.283; 95% CI, 0.16–0.49), low- or high-volume bone 
disease (HR, 0.155; 95% CI, 0.11–0.22; HR, 0.215; 95% CI, 0.16–0.29, respectively), 
and lymph node only disease (HR, 0.092; 95% CI, 0.04–0.19). For OS, HRs favored 
enzalutamide (<1) across all disease subgroups, although 95% CI was 
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>1 in patients with visceral disease (HR, 0.822; 95% CI, 0.55–1.23). 
Enzalutamide was well tolerated in patients with or without visceral disease. 
 
Conclusions: Enzalutamide provided clinically significant benefit in men with 
chemotherapy-naïve mCRPC, with or without visceral disease, low- or high-
volume bone disease, or lymph node only disease. 
 
Patient summary: Patients with mCRPC—including those with or without visceral 
disease, or widespread bone disease—benefitted from enzalutamide, an active 
well-tolerated therapy. 
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Introduction 
 
 
Prostate cancer is the second most common cancer in men, trailing only lung cancer 
in global incidence [1]. In 2012, approximately 1.1 million men worldwide were 
diagnosed with prostate cancer. In the United States, it is estimated that in 2015 there 
will be 220,080 new cases of prostate cancer and 27,540 deaths due to this disease, 
accounting for 5% of all US cancer deaths [2]. The majority of deaths occur due to 
metastatic castration-resistant prostate cancer (mCRPC), when disease progression 
occurs despite maintaining castrate levels of testosterone with medical or surgical 
castration. Bone and/or lymph node metastases are common in patients with mCRPC, 
with bone metastases contributing to skeletal-related complications that can reduce 
quality of life and increase the risk of death [3,4]. Visceral disease in the lung and/or 
liver occurs in about 20–30% of mCRPC patients and is associated with a particularly 
poor prognosis [5–10]. 
 
Until recently, standard first-line therapy for patients progressing on androgen 
deprivation therapy (ADT) was docetaxel plus prednisone [5]. Over the last few years, 
several agents with distinct mechanisms of action have demonstrated benefit in phase 
3 trials in men with asymptomatic or minimally symptomatic mCRPC who had not 
received previous chemotherapy. Sipuleucel-T, an autologous immunotherapy, 
prolonged survival but did not delay disease progression in this setting [11]. 
Abiraterone acetate, an androgen biosynthesis inhibitor, significantly improved 
radiographic progression-free survival (rPFS) and overall survival (OS) [12]. Most 
recently, the oral androgen receptor inhibitor enzalutamide significantly prolonged OS 
and rPFS in the PREVAIL trial of men with chemotherapy-naïve 
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mCRPC progressing despite ADT [13]. The benefit of enzalutamide 
was demonstrated for all prespecified secondary endpoints. 
 
The primary findings of PREVAIL were reported previously [13]. The current 
analyses focus on the effect of enzalutamide versus placebo on clinical outcomes 
in PREVAIL patients based on the extent of bone and lymph node disease at 
baseline (including those with or without visceral disease), low- or high-volume 
bone disease, or lymph node only disease. Our analyses include secondary 
outcomes in patients with only bone and or nodal soft-tissue disease, a patient 
population commonly treated by urologists and medical oncologists. 
 
 
 
Materials and Methods 
 
Study population 
 
 
Eligibility criteria for PREVAIL were described in detail previously [13]. Briefly, 
eligible patients had asymptomatic or minimally symptomatic mCRPC, an Eastern 
Cooperative Oncology Group Performance Status grade of 0 to 1, and had not 
previously received chemotherapy. PREVAIL allowed patients with visceral 
disease (metastases to the lung and/or liver). 
 
Study design and treatment 
 
 
PREVAIL was a phase 3, multinational, double-blind, randomized, placebo-controlled 
study (NCT01212991) comparing the efficacy of enzalutamide versus placebo in 
men with minimally symptomatic or asymptomatic metastatic prostate cancer who 
had not received chemotherapy. Patients were enrolled at 207 sites in 22 countries 
between September 2010 and September 2012. Patients were randomized 1:1 to 
receive either oral enzalutamide (160 mg) or placebo once daily, 
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which they continued until confirmed radiographic disease progression and 
initiation of cytotoxic chemotherapy or an investigational agent for prostate 
cancer. Randomization was central and stratified by study site. Patients were 
required to continue ADT during the study. Patients were allowed to continue or 
initiate corticosteroids. Radiation therapy and initiation of bisphosphonates or 
other approved bone-targeting agents were permitted. 
 
Study endpoints have been defined previously [13]. The coprimary endpoints 
were rPFS and OS. Secondary endpoints included time to first skeletal-related event, 
time to initiation of cytotoxic chemotherapy, best overall soft-tissue response, time to 
PSA progression, and PSA response ≥50% from baseline. Prespecified exploratory 
endpoints included quality-of-life assessments using the Functional Assessment of 
Cancer Therapy–Prostate (FACT-P) and PSA response ≥90% from baseline. 
 
Our analyses were conducted in the following subgroups: the nonvisceral 
subgroup (patients with only bone or nodal disease at screening); the visceral 
subgroup (patients with lung and/or liver metastases); the low- and high-volume 
bone disease subgroups (patients with <4 vs ≥4 bone metastases, respectively); 
and the subgroup of patients with lymph node only disease. Patients in the visceral 
subgroup may have also had bone or nodal disease. The coprimary endpoints of 
rPFS and OS were prospectively evaluated in the nonvisceral and visceral 
subgroups. All other efficacy analyses were post hoc. These included evaluation of 
secondary endpoints and an exploratory analysis of rPFS and OS in patients with 
three or fewer bone metastases at baseline and those with four or more bone 
metastases at baseline, for all patients and separately for the nonvisceral and 
visceral subgroups. For this analysis, the cutoff (<4 vs ≥4 bone metastases) was 
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selected based on the definition for high-volume disease used in the 
CHAARTED trial [14]. 
 
Statistical analysis 
 
 
A two-sided, unstratified log-rank test was used to compare rPFS and OS between 
the enzalutamide and placebo groups. Estimates of medians and 95% confidence 
intervals (CIs) were determined using the Kaplan-Meier method. Hazard ratios 
(HRs) were determined using an unstratified Cox regression model (with treatment 
as the only covariate) and were relative to placebo, with <1 favoring enzalutamide. 
Similarly, time to cytotoxic chemotherapy, FACT-P total score decline, and PSA 
progression were analyzed using the Kaplan-Meier method, log-rank test Cox 
regression model. For PSA response, only patients who had both baseline and 
postbaseline PSA assessments were included in the analysis; 95% CIs were 
reported using the Clopper-Pearson method. P values are not provided for the 
subgroup analyses as testing for statistical significance was not prespecified. 
 
The data cutoff date for all analyses (overall study population and subgroup 
analyses) was September 16, 2013, except for rPFS, which had a cutoff date of May 
6, 2012. Results from the overall study population have been previously reported. 
 
 
 
Results 
 
Patients and treatments 
 
 
Of 1717 patients randomized to treatment in PREVAIL, 1513 (88.1%) presented 
at screening with only nonvisceral disease to the bone and/or nodal disease, and 
204 (11.9%) presented with visceral disease to the lung and/or liver. In both the 
nonvisceral and visceral subgroups, patient demographics and disease 
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characteristics were generally similar between treatment groups (Table 1). 
Patients without visceral disease had lower baseline median PSA, better 
performance status, and less lymph node disease than patients with visceral 
disease, but similar rates of bone disease (Table 1). 
 
Median treatment duration with enzalutamide was 16.8 mo and 13.9 mo in 
the nonvisceral and visceral subgroups, respectively, and 4.7 mo and 3.7 mo, 
respectively with placebo. In the nonvisceral subgroup, 69.1% of patients receiving 
enzalutamide versus 19.6% receiving placebo had at least 12 mo of treatment. In 
the visceral subgroup, these percentages were 58.1% and 6.6%, respectively. 
Median follow-up for survival in the nonvisceral subgroup was 22.1 mo in the 
enzalutamide group and 22.2 mo in the placebo group, and was 22.8 mo and 24.4 
mo, respectively, in the visceral subgroup. 
 
Efficacy 
 
Primary endpoints 
 
Prespecified analyses in patients with or without visceral disease. Consistent 
with results in the overall population, treatment with enzalutamide reduced the risk 
of radiographic progression or death in both the nonvisceral (82% risk reduction; 
HR, 0.175; 95% CI, 0.14–0.22) and visceral subgroups (72% risk reduction; HR, 
0.283; 95% CI, 0.16–0.49) (Fig. 1A). In the nonvisceral subgroup, median rPFS 
was 14.1 mo with enzalutamide and 4.0 mo with placebo. In the visceral subgroup, 
median rPFS was not yet reached with enzalutamide and 3.6 mo with placebo. 
 
Enzalutamide treatment also reduced the risk of death in both the nonvisceral 
(31% risk reduction; HR, 0.692; 95% CI, 0.57–0.83) and visceral subgroups (18% risk 
reduction; HR, 0.822; 95% CI, 0.55–1.23) (Fig. 1B). In the nonvisceral subgroup, 
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median OS was not yet reached in the enzalutamide group compared with 30.2 
mo in the placebo group. In the visceral subgroup, median OS was 27.8 mo in 
the enzalutamide group and 22.8 mo in the placebo group. 
 
Post-hoc analyses by extent of baseline disease. The beneficial treatment 
effect of enzalutamide on rPFS was observed in patients with low-volume (<4 
metastases) or high-volume (≥4 metastases) bone disease (Fig. 2A), with HRs 
(HR, 0.155; 95% CI, 0.11–0.22 and HR, 0.215; 95% CI, 0.16–0.29, respectively) 
similar to those observed in the overall population. In both bone disease subsets, 
an rPFS benefit was observed in those with and those without visceral disease 
(Table 2; Supplemental Fig. 1). For OS, HRs favored enzalutamide in patients with 
low- or high-volume bone disease (HR, 0.623; 95% CI, 0.47–0.84 and HR, 0.745; 
95% CI, 0.61–0.92, respectively) (Fig. 2B). Of note, among patients with high-
volume bone disease, those with nonvisceral only disease achieved a similar OS 
benefit with enzalutamide as those with less extensive bone disease (Table 2; 
Supplemental Fig. 2A), whereas those with visceral disease showed no OS benefit 
(HR, 1.134; 95% CI, 0.69–1.86) (Table 2; Supplemental Fig. 2). 
 
Among patients with lymph node only disease at baseline, enzalutamide 
reduced the risk of radiographic progression or death by 91% versus placebo (HR, 
0.092; 95% CI, 0.04–0.19) (Table 2; Fig. 3A). Median OS in patients with lymph 
node only disease was not reached with either treatment (HR, 0.681; 95% CI, 
0.35–1.32) (Fig. 3B). 
 
Additional analyses for the nonvisceral subgroup 
 
Subsequent antineoplastic therapy. In the nonvisceral subgroup, fewer patients 
in the enzalutamide group than in the placebo group (39.7% vs 69.8%) received 
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subsequent treatment with antineoplastic agents that have previously 
demonstrated a survival benefit in metastatic prostate cancer. The two most 
common therapies used by patients after discontinuing study drug were docetaxel 
(received by 32.9% and 55.8% of patients in the enzalutamide and placebo 
groups, respectively) and abiraterone (20.3% and 46.0%, respectively). 
 
Secondary and exploratory endpoints. Post hoc analyses included evaluation of 
secondary and exploratory endpoints in the nonvisceral subgroup (Table 3). 
Enzalutamide was associated with clinically significant delays for all progression 
endpoints, including a 16.8-mo delay (28.4 vs 11.6 mo) in median time to initiation 
of cytotoxic chemotherapy (HR, 0.356; 95% CI, 0.31–0.42) (Table 3). Median time 
to PSA progression was 11.3 mo with enzalutamide versus 2.8 mo with placebo, a 
median difference of 8.5 mo (HR, 0.169; 95% CI, 0.15–0.20). Median time to 
deterioration in quality of life, as measured by a decline in FACT-P total score, was 
11.2 mo with enzalutamide versus 5.6 mo with placebo (HR, 0.626; 95% CI, 0.54– 
0.73). 
 
Confirmed PSA responses (≥50% PSA decline relative to baseline) were 
achieved by 78% of patients receiving enzalutamide versus 3.7% of patients 
receiving placebo. Confirmed PSA responses ≥90% were achieved by 47.3% of 
patients receiving enzalutamide versus 1.2% of patients receiving placebo. 
 
Safety 
 
 
Nearly all patients with or without visceral disease reported at least one 
adverse event (AE) regardless of grade or causality. In the nonvisceral and 
visceral subgroups, the incidence of common AEs and specific AEs was 
similar to that observed in the full safety population (Table 4). 
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As in the full safety population, patients with nonvisceral or visceral disease 
receiving enzalutamide had a higher incidence of grade 3 or higher events than 
those receiving placebo (42.3% vs 37.3%, nonvisceral subgroup, and 48.0% vs 
35.8%, visceral subgroup); however, median exposure to study drug was much 
longer in the enzalutamide group than the placebo group (median difference in 
length of time on enzalutamide relative to placebo of 12.1 mo in the nonvisceral 
subgroup and 10.2 mo in the visceral subgroup). In the nonvisceral subgroup, 
incidence of AEs leading to treatment discontinuation (5.6% enzalutamide vs 5.3% 
placebo) or death (3.5% vs 3.7%, respectively) was comparable between groups 
and consistent with that observed in the full population. 
 
 
 
Discussion 
 
 
Enzalutamide added to ADT at the time of progression provided clinically significant 
benefit in men with chemotherapy-naïve metastatic prostate cancer, either with or 
without visceral disease, low- or high-volume bone disease, or lymph node only 
disease. Our results suggest that enzalutamide is an active treatment in this prostate 
cancer population, irrespective of the location and extent of baseline disease. 
 
On all primary and secondary outcomes, enzalutamide demonstrated 
clinically significant benefit in patients with nonvisceral disease, who represent both 
the majority of patients in PREVAIL (88%) and a population of patients commonly 
treated by urologists and medical oncologists. Nearly half of the nonvisceral 
subgroup had lymph node disease at study entry and 85% had bone metastases (a 
rate similar to that of the visceral disease subgroup). The extended duration of 
therapy (16.8 mo) and rPFS (14.1 mo) in patients receiving enzalutamide in the 
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nonvisceral disease subgroup suggests long-term disease control in patients 
without visceral disease. In the subset of patients with lymph node only disease 
(13% of patients, nonvisceral subgroup), median rPFS was 10.4 mo longer with 
enzalutamide than with placebo. Another clinically important finding in patients with 
nonvisceral only disease was the 16.8-mo delay in median time to initiation of 
cytotoxic chemotherapy, although the study did not specify when chemotherapy 
was to be initiated; thus, this finding represents the collective decisions of patients 
and their treating physicians. The decrease in risk of PSA progression and 
improvement in radiographic response with enzalutamide provide additional 
evidence of clinical benefit. Furthermore, the benefit on time to degradation of 
FACT-P scores suggests that enzalutamide treatment may prolong quality of life. 
 
Although patients with more extensive baseline bone metastases generally 
had shorter rPFS and OS, patients with nonvisceral disease who also had 
extensive bone disease achieved a similar rPFS and OS benefit with 
enzalutamide as those with less extensive disease. A consistent rPFS and OS 
benefit was observed in patients with visceral disease who had three or fewer 
bone metastases, whereas patients with visceral disease who had 4 or more bone 
metastases had improved rPFS but not OS. It is well established that patients with 
mCRPC display a high risk for bone metastases, which contribute significantly to 
reduced quality of life and shorter survival due to bone-related complications [4]. 
Our results suggest that enzalutamide provides meaningful benefit to patients with 
mCRPC who present with either limited or widespread bone disease. 
 
Enzalutamide demonstrated a favorable safety profile that was similar between 
patients with or without visceral disease and similar to that reported previously for the 
full safety population [13]. The most common AEs included fatigue, 
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back pain, constipation, and arthralgia. Incidence of AEs leading to discontinuation 
of enzalutamide was low (6%) in both visceral and nonvisceral disease subgroups, 
suggesting good tolerability over an extended treatment duration. The incidence of 
hypertension was higher with enzalutamide than with placebo in both the 
nonvisceral (14% vs 4%) and visceral (11% vs 4%) subgroups. As described 
previously [13], hypertension in this study was most often reported in patients with 
a prior history of hypertension and was generally managed with standard therapies. 
Enzalutamide was not associated with a higher incidence of seizure in this study 
(one patient [0.1%] in each treatment group). In an earlier phase 3 study (AFFIRM) 
of enzalutamide in men with mCRPC who had previously received chemotherapy, 
0.6% of enzalutamide-treated patients experienced a seizure [15]. 
 
 
 
Conclusions 
 
 
In our study, enzalutamide provided meaningful clinical benefit to men with 
chemotherapy-naïve mCRPC, with or without visceral disease, low- or high-volume 
bone disease, or lymph node only disease. Patients without visceral disease 
particularly benefitted from enzalutamide, an active therapy with good tolerability 
that allowed for a long duration of treatment. Similar benefit was observed for 
patients with visceral disease who also had low-volume metastases to bone. 
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 Table 1 – Baseline patient and disease characteristics               
    
 
   
 
 
 
    
 
 
 
   
    Nonvisceral Subgroup  Visceral Subgroup  Overall ITT Population 
     (n = 1513)    (n = 204)    (n = 1717) 
     Enzalutamide   Placebo    Enzalutamide    Placebo    Enzalutamide   Placebo 
    (n = 774)   (n = 739)   (n = 98)    (n = 106)   (n = 872)   (n = 845) 
 Baseline characteristics                    
 Age, yr, median (range)   71 (44–93)  71 (42–93)   73 (43–88)    71 (53–89)   72 (43–93)   71 (42–93) 
 
Gleason score ≥8 at initial diagnosis, % 
    
53.0 
          
  51.2     45.7  48.0   50.6  52.4 
 
ECOG PS grade = 0, % 
    
70.1 
          
  67.8     60.2  63.2   67.0  69.2 
 
Baseline pain 0–1 on BPI-SF Q3, % 
    
68.3 
          
  66.8     61.9  61.9   66.2  67.5 
 
Baseline use of corticosteroids,% 
    
4.3 
          
  3.7     6.1  3.8   4.0  4.3 
 
Baseline use of bone targeting agents, % 
    
27.3 
          
  25.3     27.6  26.4   25.5  27.1 
 
Prior antiandrogen use, % 
    
85.9 
          
  87.6     83.7  89.6   87.2  86.4 
 
Prior radical prostatectomy, % 
    
27.5 
          
  25.7     27.6  20.8   25.9  26.6 
 
Median PSA, ng/mL 
    
42.3 
          
  51.1     80.0  70.4   54.1  44.2 
 
Median LDH, IU/L 
    
184.0 
          
  184.0     188.0  201.0   185.0  185.0 
 
Bone disease, % 
    
82.0 
          
  85.4     81.6  79.2   85.0  81.7 
 
Lymph node, % 
    
50.6 
          
  49.0     59.2  56.6   50.1  51.4 
 
Soft-tissue disease, %* 
    
53.9 
          
  54.1     100  100   59.3  59.6 
 
*Lymph node, visceral, or other. 
                     
                      
 
BP-SF Q3 = Brief Pain Inventory Short Form Question 3; ECOG = Eastern Cooperative Oncology Group; ITT = intent-to-treat; LDH = lactate 
dehydrogenase; PS = performance status; PSA = prostate-specific antigen. 
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Table 2 – Radiographic progression-free survival and overall survival by extent and location of disease at baseline    
                         
    <4 Bone Metastases      ≥4 Bone Metastases     
Lymph Node Only All Patients   Nonvisceral  Visceral  Nonvisceral  Visceral  
  ENZA  PBO  ENZA  PBO  ENZA  PBO  ENZA   PBO  ENZA  PBO  ENZA  PBO 
  (n = 393)  (n = 377)  (n = 48)  (n = 49)  (n = 381)  (n = 362)  (n = 50)   (n = 57)  (n = 87)  (n = 108) (n = 872)  (n = 845) 
Median  NYR  NYR  32.4  NYR  28.0  26.0  18.9   18.3  NYR  NYR   32.4  30.2 
OS, mo  HR,  0.644  HR,  0.518  HR,  0.695  HR,  1.134  HR,  0.681   HR,  0.706 
  (95% CI, 0.47–0.89)  (95% CI, 0.25–1.07)  (95% CI, 0.55–0.88)  (95% CI, 0.69–1.86)  (95% CI, 0.35–1.32) (95% CI, 0.60–0.84) 
                        p < 0.0001 
Median  14.1  5.2  NYR  3.6  NYR  4.0  10.9   3.9  14.1  3.7   NYR  3.9 
rPFS, mo  HR,  0.159  HR,  0.130  HR,  0.185  HR,  0.479  HR,  0.092   HR,  0.186 
  (95% CI, 0.11–0.23)  (95% CI, 0.05–0.35)  (95% CI, 0.13–0.26)  (95% CI, 0.24–0.95)  (95% CI, 0.04–0.19) (95% CI, 0.15–0.23) 
                 p < 0.0001 
CI = confidence interval; ENZA = enzalutamide; HR = hazard ratio; NYR = not yet reached; PBO = placebo. 
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Table 3 – Secondary efficacy outcomes in the nonvisceral subgroup 
 
    Enzalutamide   Placebo  HR (95% CI) 
 
Endpoint 
  (n = 774)   (n = 739)   
         
         
Median time to initiation of cytotoxic  28.4  11.6  0.356 (0.31–0.42) 
chemotherapy, mo (95% CI)   (25.8–NYR)   (10.0–13.1)   
       
Median time to PSA progression, mo  11.3  2.8  0.169 (0.15–0.20) 
(95% CI)*   (11.1–13.8)   (2.8–2.9)   
       
Median time to decline in the FACT-P  11.2  5.6  0.626 (0.54–0.73) 
total score, mo (95% CI)
†   (11.1–13.9)   (5.3–5.6)   
Confirmed change in PSA         
 Patients with ≥1 postbaseline PSA  
765 (98.8) 
 
684 (92.6) 
  
 
assessment, n (%) 
    
         
          
 PSA decline of ≥50% from baseline,  
597/765 (78.0) 
 
25/684 (3.7) 
  
 
n/total N (%) 
    
         
          
 PSA decline of ≥90% from baseline,  
362/765 (47.3) 
 
8/684 (1.2) 
  
 
n/total N (%) 
    
         
          
*PSA progression defined by PCWG2 criteria.  
†
FACT-P decline defined as ≥10-point decrease in total score. 
 
CI = confidence interval; FACT-P = Functional Assessment of Cancer Therapy–Prostate; HR = 
hazard ratio; NYR = not yet reached; PCWG2 = Prostate Cancer Working Group; PSA = 
prostate-specific antigen. 
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Table 4 – Most common and specific adverse events 
 
 
 
 
Adverse Events 
 
Any adverse event, n (%) 
 
Any adverse event leading to 
treatment discontinuation, n (%) 
 
Most common adverse events, n (%)* 
 
 
Nonvisceral Subgroup    Visceral Subgroup   Overall Safety Population 
 (n = 1511)     (n = 204)     (n = 1715)  
Enzalutamide   Placebo   Enzalutamide    Placebo   Enzalutamide   Placebo 
(n = 773)   (n = 738)   (n = 98)    (n = 106)   (n = 871)   (n = 844) 
750 (97.0)  689 (93.4)  94 (95.9)    98 (92.5)  844 (96.9)  787 (93.2) 
43 (5.6) 
  
(5.3) 
  
(6.1) 
   
12 (11.3) 
  
(5.6) 
  
(6.0)  39  6     49  51 
                      
 
Fatigue 282#(36.5) 192 (26.0) 28 (28.6) 26 (24.5) 310 (35.6) 218 (25.8) 
Back pain 
   
(25.5) 
 
(22.6) 
  
(22.2) 210#(27.2) 163#(22.1) 25 24 235 (27.0) 187 
Constipation 
   
(26.5) 
 
(18.9) 
  
(17.2) 167#(21.6) 125#(16.9) 26 20 193 (22.2) 145 
Arthralgia 
   
(17.3) 
 
(11.3) 
  
(16.0) 160#(20.7) 123#(16.7) 17 12 177 (20.3) 135 
Specific adverse events, n (%) 
          
          
Hypertension 
   
(11.2) 
 
(3.8) 
  
(4.1) 106#(13.7) 31#(4.2) 11 4 117 (13.4) 35 
Any cardiac adverse event 
   
(12.2) 
 
(6.6) 
 
(10.1) 
 
(7.8) 76#(9.8) 59#(8.0) 12 7 88 66 
ALT increased 
   
(2.0) 
 
(1.9) 
 
(0.9) 
 
6#(0.8) 3#(0.4) 2 2 8 5 (0.6) 
Seizure 1#(0.1)
† 
  
0 
 
(0.9) 1 (0.1)
† 
 
0  1 1 (0.1) 
           
*Included in this category are adverse events that were reported in the overall safety population in ≥10% of patients in the enzalutamide group at a rate 
that was ≥2% higher than that in the placebo group. 
†
This seizure occurred after the data cutoff 
date. ALT = alanine aminotransferase. 
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Figures 
 
Fig. 1 – Kaplan-Meier estimates of (A) rPFS and (B) OS in the 
overall population and in the nonvisceral and visceral subgroups. 
 
CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; OS = 
overall survival; rPFS = radiographic progression-free survival. 
 
 
Fig. 2 – Kaplan-Meier estimates of rPFS (A) and OS (B) by number of 
bone metastases at screening (<4 vs ≥4). 
 
CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; mets 
= metastases; OS = overall survival; rPFS = radiographic progression-
free survival. 
 
Fig. 3 – Kaplan-Meier estimates of (A) rPFS and (B) OS in the subgroup 
of patients with lymph node only disease. 
 
CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; OS = 
overall survival; rPFS = radiographic progression-free survival. 
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